Com.Pl.it DX® Lung Cancer
provides a detailed blueprint of the biology of the tumor by analyzing many genes at the same time, which is used by the treating physician to design the most accurate treatment plan for each patient.
Com.Pl.it DX® Lung is focused on patients with Non-Small-Cell Lung Carcinoma (NSCLC) and it is designed to achieve maximum sensitivity and specificity.
All findings are classified using the most reliable and updated databases and in silico analysis algorithms. The analysis of gene fusions is also included in Com.Pl.it DX®, providing comprehensive and reliable information to patients and physicians.
Next Generation Sequencing (NGS) technology is used for the simultaneous analysis of many genes alterations using the same sample, thus saving valuable material.
The Com.Pl.it DX® Lung Cancer test:
- Determines the molecular profile (gene mutations) of the tumor and of interactions between genes in case of multiple mutations.
- Designates the on-label drug (if it exists) that targets the mutated gene(s) or the pathway that the gene(s) are involved in.
- Identifies mutations associated with resistance to targeted treatment.
- Assigns off-label treatments or ongoing clinical trials based on tumor’s molecular profile.
This could be particularly important for patients who have failed conventional therapy.
Table of Genes Analyzed
27 gene alterations
AKT1 | ALK | BRAF | CDKN2A | CTNNB1 | DDR2 |
EGFR | ERBB2 | FBXW7 | FGFR1 | FGFR2 | FGFR3 |
HRAS | KEAP | KRAS | MAP2K1 | MET | NOTCH1 |
NRAS | PIK3CA | POLE | PTEN | RET | SMAD4 |
SMARCA4 | STK11 | TP53 |
7 fusion transcripts
ALK | ROS1 | RET | NTRK1 | NTRK2 | NTRK3 | MET |
Immunotherapy Biomarkers
PD-L1 |
FAQs
Genekor’s Validation Studies for Com.Pl.it DX® Lung
“The use of sensitive mutation detection techniques in a large study population of Greek NSCLC patients in routine diagnostic practice revealed an overall EGFR mutation frequency of 15.83%. Of note, there was a 99.8% concordance between the HRM method and Sanger sequencing. NGS was found to be the most sensitive method.”
Papadopoulou E, Tsoulos N, Tsirigoti A, Apessos A, Agiannitopoulos K, Metaxa-Mariatou V, Zarogoulidis K, Zarogoulidis P, Kasarakis D, Kakolyris S, Dahabreh J, Vlastos F, Zoublios C, Rapti A, Papageorgiou NG, Veldekis D, Gaga M, Aravantinos G, Karavasilis V, Karagiannidis N, Nasioulas G. Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients. Oncol Lett. 2015 Oct;10(4):2176-2184.
“In total, alterations in a cancer-driver gene were identified in 77.6% of the tumors tested. Among the NSCLC patients, 23% presented a mutation in a gene associated with approved or emerging targeted therapy. Thus, the targeted NGS panel used in this study is a reliable approach for tumor molecular profiling and can be applied in personalized treatment decision making for NSCLC patients.”
Tsoulos N, Papadopoulou E, Metaxa-Mariatou V, Tsaousis G, Efstathiadou C, Tounta G, Scapeti A, Bourkoula E, Zarogoulidis P, Pentheroudakis G, Kakolyris S, Boukovinas I, Papakotoulas P, Athanasiadis E, Floros T, Koumarianou A, Barbounis V, Dinischiotu A, Nasioulas G. Tumor molecular profiling of NSCLC patients using next generation sequencing. Oncol Rep. 2017 Dec;38(6):3419-3429.